S*Bio presents positive safety and tolerability results for its oral JAK2 inhibitor SB1518 for the treatment of myelofibrosis
15-Jun-2010 -
S*BIO Pte Ltd announced the presentation of positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for its novel oral JAK2 inhibitor, SB1518, at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Barcelona, Spain.
Data was presented on the ...
hematology
inhibitors
myelofibrosis
+4